On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids.
On June 16, 2010, Neurocrine entered into a financial agreement with AbbVie Inc. (formerly Abbott Laboratories), worth up to $575 million, which included granting AbbVie the rights to develop and market elagolix, an oral medication that blocks GnRH hormones for managing endometriosis and uterine fibroids.